April 30, 2012
The clinical symptoms of persistent and nonpersistent chronic constipation (CC) are similar, with persistent CC estimated to have a prevalence of 3%.
March 05, 2012
For critically ill patients with opioid-induced constipation, treatment with methylnaltrexone (MNTX) is associated with improved bowel function compared with standard rescue therapy.
October 24, 2011
The FDA has accepted for review the New Drug Application (NDA) for linaclotide (Forest and Ironwood) for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).
August 30, 2011
Progenics Pharmaceuticals and Salix Pharmaceuticals announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Relistor (methylnaltrexone bromide) Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.
Methylnaltrexone bromide, a selective peripherally acting mu-opioid receptor antagonist, is effective for the long-term treatment of opioid-induced constipation resulting from chronic opioid therapy in chronic non-cancer pain, as demonstrated by study data presented at the American Pain Society's 30th Annual Scientific Meeting.